Novel Targets for Therapy of Renal Fibrosis

Area of Science:

• Nephrology
• Molecular Biology
• Pathology

Background:

• Chronic kidney disease (CKD) is a progressive, incurable condition with increasing global prevalence.
• Current treatments for end-stage renal disease (ESRD) rely on renal replacement therapy, highlighting the need for novel therapeutic strategies.
• Renal fibrosis is a key pathological feature of CKD, driving disease progression.

Purpose of the Study:

• To identify and characterize novel molecular mediators involved in the development and progression of renal fibrosis.
• To evaluate the therapeutic potential of targeting these identified mediators in experimental models of kidney disease.

Main Methods:

• Utilized experimental models of renal disease and human patient biopsies to identify potential therapeutic targets.
• Investigated the expression levels and localization of candidate mediators in diseased kidneys.
• Employed gene deletion, antisense administration, and specific blockers to inhibit candidate proteins in vivo.
• Assessed the impact of inhibition on renal structure and function.

Main Results:

• Identified four novel mediators: discoidin domain receptor 1, periostin, connexin 43, and cannabinoid receptor 1, which were upregulated in renal disease models.
• Demonstrated that these mediators are centrally involved in the mechanisms driving renal fibrosis progression.
• Showed that inhibition of these mediators, even after disease onset, delayed progression and preserved kidney function and structure.

Conclusions:

• Discoidin domain receptor 1, periostin, connexin 43, and cannabinoid receptor 1 are promising therapeutic targets for combating renal fibrosis.
• Targeted inhibition of these mediators offers a potential strategy to slow or halt the progression of chronic kidney disease.
• These findings open new avenues for developing treatments to preserve renal health and function.